Rebound increases in chemokines by CXCR2 antagonist in breast cancer can be prevented by PKC delta and PKC epsilon activators

ERİN, NURAY; Tavsan, ESRA; Akdeniz, Ozlem; Isca, Vera; Rijo, Patricia

doi:10.1016/j.cyto.2021.155498

Rebound increases in chemokines by CXCR2 antagonist in breast cancer can be prevented by PKC delta and PKC epsilon activators

Atıf İçin Kopyala

ERİN N., Tavsan E., Akdeniz O., Isca V. M. S., Rijo P.

CYTOKINE, cilt.142, 2021 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 142
Basım Tarihi: 2021
Doi Numarası: 10.1016/j.cyto.2021.155498
Dergi Adı: CYTOKINE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Akdeniz Üniversitesi Adresli: Evet

Özet

Activation of CXCR2 by chemokines such as CXCL1 and CXCL2 increases aggressiveness of breast cancer, inducing chemoresistance, hence CXCR2 antagonists are in clinical trials. We previously reported that inhibition of CXCR2 increases MIP-2 (CXCL2), which may inhibit anti-tumoral effects of CXCR2 antagonists. This seems to be due to inhibition of protein kinase C (PKC) by CXCR2 antagonist since specific inhibitor of PKC also enhances MIP-2 secretion.